Table 2 Proportion of cases averted by each targeted vaccination strategies in each MERS and SAR healthcare setting outbreak
Outbreak | Vaccinated Population | Proportion Vaccinated | Proportion of Cases Averted (95% CI) |
|---|---|---|---|
Singapore (SARS) | HCW | 0.50 | 0.22 (0.14–0.30) |
Singapore (SARS) | HCW | 0.75 | 0.36 (0.26–0.45) |
Singapore (SARS) | HCW | 1.00 | 0.89 (0.83–0.95) |
South Korea (MERS) | HCW | 0.50 | 0.06 (0.01–0.11) |
South Korea (MERS) | HCW | 0.75 | 0.10 (0.04–0.16) |
South Korea (MERS) | HCW | 1.00 | 0.13 (0.06–0.19) |
Toronto (SARS) | HCW | 0.50 | 0.18 (0.10–0.25) |
Toronto (SARS) | HCW | 0.75 | 0.27 (0.18–0.36) |
Toronto (SARS) | HCW | 1.00 | 0.39 (0.29–0.48) |
Singapore (SARS) | Patients | 0.50 | 0.43 (0.34–0.53) |
Singapore (SARS) | Patients | 0.75 | 0.57 (0.47–0.67) |
Singapore (SARS) | Patients | 1.00 | 0.71 (0.62–0.80) |
South Korea (MERS) | Patients | 0.50 | 0.59 (0.49–0.69) |
South Korea (MERS) | Patients | 0.75 | 0.76 (0.67–0.84) |
South Korea (MERS) | Patients | 1.00 | 0.87 (0.80–0.93) |
Toronto (SARS) | Patients | 0.50 | 0.47 (0.37–0.57) |
Toronto (SARS) | Patients | 0.75 | 0.67 (0.57–0.76) |
Toronto (SARS) | Patients | 1.00 | 0.89 (0.83–0.95) |